New Jersey, United States,- The research report on Complementary And Alternative Medicine market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The unit cost deployed by these producers in various regions during the estimated timeframe is also mentioned in the report.

Significant information pertaining to the product volume and consumption value is enlisted in the document. Additionally, the report contains details regarding the consumption graphs, Individual sale prices, and import & export activities. Additional information concerning the production and consumption patterns are presented in the report.

In a word, the Complementary And Alternative Medicine Market report provides major statistics on the state of the Complementary And Alternative Medicine industry with a valuable source of guidance and direction for companies and individuals interested in the market. In the end, Complementary And Alternative Medicine Market report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Regions Covered in the Global Complementary And Alternative Medicine Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2020-2026

Identification and in-depth assessment of growth opportunities in key segments and regions

Detailed company profiling of top players of the global Complementary And Alternative Medicine market

Exhaustive research on innovation and other trends of the global Complementary And Alternative Medicine market

Reliable industry value chain and supply chain analysis

Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Complementary And Alternative Medicine marketwith a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Complementary And Alternative Medicine market.

Reasons to Buy the Report:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the original post:

Complementary And Alternative Medicine Market Applications, Types and Future Outlook Report 2020-2027 - Bulletin Line

The report covers the forecast and analysis of the Brazil Complementary and Alternative Medicine market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million).

The study includes drivers and restraints of the Brazil Complementary and Alternative Medicine market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Brazil Complementary and Alternative Medicine market on a global level.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10172662

In order to give the users of this report a comprehensive view of the Brazil Complementary and Alternative Medicine market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Brazil Complementary and Alternative Medicine market by segmenting the market based on type, age group, disease indications, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A combination of various technologies will pave the way for the market growth in Brazil over the forecast timeline. Moreover, the occurrence of non-contagious ailments like heart disorders, high blood pressure, diabetes, and depression will propel the market growth during the period from 2019 to 2027. In addition to this, the complementary & alternative drugs approach for treating these non-communicable ailments will create lucrative growth avenues for the industry in other developing regions also. Apart from this, the integration of therapies like acupuncture and magnetic interventions will further boost the complementary and alternative medicine industry in Brazil.

Based on the type, the market for complementary and alternative medicine in Brazil is divided into Traditional Alternate Medicine Therapy, Diet and Herbal Based Therapy, Mind Therapy, Body Therapy, and Energy Healing Therapy. In terms of age group, the industry is classified into Infant, Adults, Adolescent, and the Elderly.

Request For Full Report:https://www.kennethresearch.com/sample-request-10172662

On the basis of disease indications, the market is divided into Arthritis, Neurology, Cancer, Cardiology, Asthma, and Diabetes. In terms of distribution channel, the market is segmented into Direct Sales, Distance Correspondence, and E-Distribution.

Some of the key players in the market include Optum, Inc., Ach, Quantum-Touch, and Herboflora.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Read the rest here:

Brazil Complementary And Alternative Medicine Market Segments and Supply Demand Forecast 2020-2027 - Bulletin Line

1. When compared to 9 months of isoniazid, 4 months of rifampin was a non-inferior alternative treatment of latent tuberculosis (TB) that was both cheaper and lead to lower healthcare usage amongst adult and pediatric patients in high-, middle-, and low-resource health systems in 9 nations.

2. Choosing rifampin represented a cost savings of 38% to the health system

Evidence Rating:1 (Excellent)

Study Rundown:Isoniazid, an inhibitor of mycobacteria cell wall synthesis, is the standard of treatment of latent TB. Rifampin, a more costly medication, is generally reserved for active TB treatment along with ethambutol and pyrazinamide. This study demonstrated that while rifampin is more expensive, its shorter treatment length and fewer adverse events resulted in a lower total cost across study sites. Ultimately this represented a cost savings to the health system of roughly one-third of the cost of isoniazid. The studys applicability was strengthened by its multi-centered approach that included representative countries across GDP. The failure to include individual cost burden limited the studys ability to fully account for possible barriers to treatment.

Click to read the study in Annals of Internal Medicine

In-Depth[randomized controlled trial]:This multicenter, prospective, open-label randomized controlled trial examined the cost of treatment for latent TB with isoniazid and rifampin across 9 diverse study countries (Australia, Benin, Brazil, Canada, Ghana, Guinea, and Indonesia). Participant eligibility was determined by documented skin test or QuantiFERON test, clinical risk factors, and clinician treatment recommendation. Baseline characteristics were attained from each participant including blood tests, chest radiography, and clinician medical assessment as were health data from routine follow ups with clinicians (which included attaining a complete blood count and liver function test). Six-thousand twelve adults and 829 children were included in the final modified intent-to-treat analysis with roughly half of the population originating from African countries. Seventy-one percent of adults and 82% of children completed treatment and 229 participants experienced an adverse event. The total cost of 9 of months of isoniazid was higher than 4 months of rifampin across all 9 study sites. Total cost was also higher in high-income countries when compared to middle-income or African countries. Cost components were heterogeneously distributed amongst the 3 income groups: routine follow-up visits made up 30 50% of total cost in high- and middle-income countries compared to roughly 15% of the cost in African countries. After multivariate analysis, the total average cost of rifampin was $340 (CI 95% $330 to $350) which represented a 38% savings for the health systems.

20202 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from2 Minute Medicine, Inc. Inquire about licensinghere. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Read more:

#VisualAbstract: Treating latent tuberculosis infection with four months of rifampin versus nine months of isoniazid - 2 Minute Medicine

Re: the July 23 letter "Vote because your life depends on it."

The letter illustrates that some of the distrust of the medical profession that is hindering the fight against COVID-19 has been well-earned. Women with chronic debilitating symptoms are dismissed as psychiatric cases, while people of color cannot get treatment for pain. Research into the devastating epidemics of chronic fatigue syndrome, Lyme disease, and autism is underfunded in favor of research into expensive treatments for rare diseases. The CDC and Dr. Fauci's NIAID ignore evidence that Lyme bacteria can persist in the body and cause years of disability, fail to develop accurate tests for Lyme, and discredit labs that offer better tests.

This neglect drives many patients into alternative medicine, where some find healing and some learn distrust of Western science, including vaccines. Perhaps the public's maddening response to the pandemic will lead to a re-evaluation of medicine's practices and priorities.

Disclaimer: As submitted to the Arizona Daily Star.

View post:

Letter: Reaping what you sow | Letters to the Editor - Arizona Daily Star

The blending of marijuana with other pharmaceutical products for the purpose of medical treatment is being given the go-ahead by the Thai government. Nation Thailand reports that the Ministry of Public Health has approved 17 formulations for use in local health promotion hospitals.

Sub-district Health Promoting Hospitals are hospitals that are operated by either the MOPH or Department of Local Administration and were initially called health stations. These hospitals only have primary care capabilities and often serve villages within districts. Almost all of these hospitals do not accept inpatients and usually have no doctor on duty for the entire time. Wikipedia

Dr. Marut Jirasrattasiri, from the Department of Traditional Thai Medicine and Alternative Medicine, says over 60,000 patients have expressed interest in being treated with medicinal marijuana, with the department approving the drug for use.

Currently, 4 hospitals are understood to be participating, 3 of which are in the north-east of the country. These are Khlong Muang Hospital in Nakhon Ratchasima province, Chiang Phin Hospital in the province of Udon Thani, Ban Na Yao Nuea Hospital in Sakon Nakhon province, and Ban Na Pak Khow hospital in the southern province of Phatthalung.

SOURCE: Nation Thailand

Read more:

Thailand approves use of marijuana in local health promotion hospitals - The Thaiger

This advertorial is sponsored by Bentley.

Maria Antonella Ruffino, a vascular interventional radiologist at Azienda Ospedaliera Universitaria Citt della Salute e della Scienza in Turin, Italy, tells Vascular News about her teams growing clinical experience with covered stents as a platform that offer a minimally invasive solution for arterial emergencies. Ruffino gives an insight into the advantages of covered stents in such cases, their potential limitations, and which ones may be a favourable option for emergency treatment.

Arterial emergencies, such as bleeding, pseudoaneurysm, dissection, or fistula are potentially life-threatening conditions. Spontaneous or iatrogenic arterial emergencies require prompt diagnosis and treatment. During the last few decades, the treatment of these lesions has shifted from emergency open surgery to an endovascular approach, and the latter is rapidly becoming part of the treatment algorithm.

What are the advantages of using covered stents in such emergency cases?

The main endovascular approaches include use of covered stents and embolisation. A key advantage of using a covered stent in an emergency case, when compared to embolisation, is that a stent graft guarantees the immediate exclusion of the lesion without the sacrifice of the target vessel, avoiding the risk of non-target embolisation, which can result in ischaemic complications and rebleeding. Preservation of flow is crucial particularly in districts with a terminal vascularisation, without collaterals, such as the limbs and kidneys. Additionally, this also applies to the liver, where it is uncertain whether extrahepatic arteries provide sufficient collateral circulation in case of hepatic artery occlusion.

What is your clinical experience with covered stents?

At our centre, we started using the BeGraft peripheral stent graft (Bentley, Hechingen, Germany) in June 2015. In the beginning, we used it for iliac procedures in elective cases of severe aortoiliac occlusive disease. Subsequently, we expanded this to include cases of rupture or dissection, and for severe complications that can present when long, calcified iliac occlusions are treated. The availability, wide sizing range, goodtrackability and conformability of these stent grafts and their low profile (6F compatible up to 8mm diameter) led us to extend their use to other vessels in case of arterial injuries. Since 2018, we have also used the BeGraft aortic stent graft, which has allowed us to treat vessels of larger diameters. Our cardiology colleagues already use the BeGraft coronary stent.

During the last few years, we have treated many emergency cases with the BeGraft stent graft family. These include iliac ruptures or renal pseudoaneurysms which are quite common but also more complex cases, like common carotid artery bleeding or penetrating aortic ulcer rupture.* In these last two scenarios, in particular, where we needed a large stent graft (12mm), we have experienced first-hand how a larger diameter BeGraft stent can perform in tortuous anatomies, thanks to its good trackability and low profile, as it can be used with small vascular sheaths (9F in these cases).

Part of our experience, which focused on iatrogenic arterial injuries, has been recently published in Medicine, reporting a technical success of 100% and a clinical success of 88%. No device- or procedure-related deaths, nor major complications were reported. There was no patency loss at mid-term follow-up (average FU 390 +/- 168 days).1

Are there any limitations associated with the use of covered stents for emergency cases?

Almost all arterial lesions can be treated with covered stents, except for those without anatomic suitability, such as very distal lesions, or those without an adequate proximal and distal neck. Similarly, arterial lesions that are located in vessels of a calibre not suitable for stenting cannot be treated with covered stents. Finally, in case of tortuous anatomy or at a joint, when possible, a self-expandable covered stent is the preferred option.

What are your must-have sizes of covered stents for emergencies?

Arterial emergencies can present with a variety of lesions that can be very different in aetiology and characteristics, and located in vessels that can vary significantly in size. This is why we require a wide array of differently sized stent grafts in order to select the most suitable one. It is, therefore, difficult to say which sizes are a must-have.

Our experience shows that, in the case of arterial injuries, the proper sizing of the stent graft is essential to achieve technical and clinical success, without complications and recurrences, which further highlights the importance of having a wide range of stent grafts on shelf to treat arterial emergencies, and the BeGraft family has the broadest covered stent platform in the market.

Overall, endovascular treatment with BeGraft covered stents, with preservation of distal flow, is minimally invasive, safe, and effective in the management of arterial injuries and emergencies. Furthermore, all the aforementioned device characteristics allow for the rapid treatment of the lesion, even in case of tortuous anatomy.

*The usage of the BeGraft aortic for treatment in the carotid artery or PAU is off label.

References

Case images

See the article here:

Balloon-expandable covered stent reveals promise as endovascular alternative to surgery in treatment of arterial emergencies - Vascular News

Image courtesy of HK Yalamanchili/Liu lab/Nucleic Acids Research, 2020

Researchers with an interest in unraveling gene regulation in human health and disease are expanding their horizons by closely looking at alternative polyadenylation (APA), an under-charted mechanism that regulates gene expression.

APA is about modifying one of the ends, called the 3-prime end (3end), of RNA strands that are transcribed from DNA. The modification consists of changing the length of a tail of adenosines, one of the RNA building blocks, at the 3end before RNA is translated into proteins, said first author Dr. Hari Krishna Yalamanchili, a postdoctoral associate in the lab of Dr. Zhandong Liu at Baylor College of Medicine. This adenosine chain helps to determine how long the messenger RNA lasts in the cell, influencing how much protein is produced from it.

The interest in APA has resulted in the development of several 3 sequencing (3Seq) techniques that allow for precise identification on APA sites on RNA strands. But what researchers are missing is a robust computational tool that is specifically designed to analyze the wealth of 3Seq data that has been generated.

Until now, researchers have been using traditional RNA sequencing computational tools to analyze the 3Seq datasets. Although this approach produces results, it does not maximize the potential amount of information that can be extracted from that data, Yalamanchili said. Here we developed a computational tool that precisely analyzes 3Seq data. We call it PolyA-miner.

Yalamanchili and his colleagues used their new computational tool to analyze existing 3Seq datasets. PolyA-miner not only reproduced the analyses achieved with traditional computational tools, but also identified novel APA sites that were not detected with the other analytical approaches.

We were surprised when the PolyA-miner analysis of a glioblastoma cell line dataset identified more than twice the number of genes with APA changes than were initially reported, Yalamanchili said.

I think that the most exciting part of this new tool is that it enables us to precisely reflect gene-level 3 changes and to identify many more APA events than before. With other analytical approaches, we underestimate the effect and number of poly-adenylation events, said Liu, associate professor of pediatrics and neurology at Baylor and the Jan and Dan Duncan Neurological Research Institute at Texas Childrens Hospital.

This development has tremendous implications for basic research and for the potential translation of scientific findings into the clinic. APA is considered a major mechanism for RNA regulation that has strong relevance both in cancer and neurological diseases. PolyA-miner can assist scientists looking to identify the genetic causes of these diseases by determining whether there are differences in APA between diseased and normal cells. With this new analysis, scientists can take a fresh look at existing genomic datasets that may provide an answer to the cause of human conditions, as well as studying newly developed datasets.

Previously, people knew about APA changes, but did not consider them to be major contributors to gene regulation mainly because we lacked the computational tools to determine APAs overall influence on gene expression, Yalamanchili said.

PolyA-miner has shown that APA seems to play a larger role in gene regulation than we had previously thought.

Read the complete article in the journal Nucleic Acids Research.

Other contributors to this work include Callison E. Alcott, Ping Ji, Eric J. Wagner and Huda Y. Zoghbi. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine; Jan and Dan Duncan Neurological Research Institute at Texas Childrens Hospital; University of Texas Medical Branch, Galveston; and Howard Hughes Medical Institute, Houston.

Financial support for this project was provided by Cancer Prevention Research Institute of Texas (RP170387), Houston endowment, Chao endowment, Huffington foundation, Howard Hughes Medical Institute, NRI Zoghbi Scholar Award, National Institute of Neurological Disorders and Stroke (F30NS095449), National Institute of General Medical Sciences [R01-GM134539) and the National Cancer Institute (R03-CA223893-01).

By Ana Mara Rodrguez, Ph.D

More here:

PolyA-miner accurately assesses the effect of alternative polyadenylation on gene expression - Baylor College of Medicine News